Testing effectiveness (Phase 2)Ended earlyNCT00503971
What this trial is testing
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Who this might be right for
Non-small Cell Lung Cancer
Spanish Lung Cancer Group 33